Crinetics Pharmaceuticals

CRNX

Market cap $3.22B

Overview Fund Activity

34.20 USD

+0.10

0.29%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

34.46

+0.26

0.76%

1 day

0.29%

5 days

-0.87%

1 month

15%

3 months

10.86%

6 months

-2.84%

Year to date

-33.66%

1 year

-35.46%

5 years

112.42%

10 years

39.53%

About: Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.

Employees: 437

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

634% more call options, than puts

Call options by funds: $3.14M | Put options by funds: $428K

50% more repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 64

2.16% more ownership

Funds ownership: 109.51% [Q1] → 111.68% (+2.16%) [Q2]

5% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 37

2% less funds holding

Funds holding: 226 [Q1] → 221 (-5) [Q2]

12% less capital invested

Capital invested by funds: $3.42B [Q1] → $3.01B (-$412M) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 9 [Q1] → 6 (-3) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$81

137% upside

Avg. target

$84

144% upside

High target

$86

151% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities Jonathan Wolleben	$86	Market Outperform Maintained	11 Aug 2025
HC Wainwright & Co. Douglas Tsao	$81	Buy Reiterated	27 Jun 2025

See Analyst Rankings

Financial journalist opinion

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 62,475 shares of its common stock and granted an aggregate of 43,800 restricted stock unit (“RSU”) awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH). Atumelnant is the first and only small molecule ACTH receptor antagonist in clinical development.

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an aggregate of 53,400 restricted stock unit (“RSU”) awards to 27 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2025 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alan S. Krasner - Corporate Participant Chief Endocrinologist - Corporate Participant Dana Pizzuti - Chief Medical & Development Officer Gayathri Diwakar - Head of Investor Relations Isabel Kalofonos - Chief Commercial Officer R.

Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2025 Earnings Call Transcript

The Motley Fool

Crinetics (CRNX) Q2 Revenue Jumps 150%

Crinetics (CRNX) Q2 Revenue Jumps 150%

Crinetics (CRNX) Q2 Revenue Jumps 150%

Zacks Investment Research

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $0.94 per share a year ago.

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date Continued Progress on the Global Development Program for Atumelnant Across Multiple Trials, Including the BALANCE-CAH Phase 2/3 Study for the Treatment of Children with Congenital Adrenal Hyperplasia Expected to Initiate this Year $1.2B in Cash, Cash Equivalents, and Investment Securities as of June 30, 2025 Anticipated to Provide Runway into 2029 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the second quarter ended June 30, 2025.

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Zacks Investment Research

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

See News Rankings

Charts implemented using Lightweight Charts™